BriaCell partners with MSK accelerator for breast cancer therapy Oct 21, 2025 07:31AM
BriaCell study validates Bria-OTS+ cancer therapy mechanism Aug 26, 2025 07:38AM
BriaCell sets August 25 as effective date for 1-for-10 share consolidation Aug 21, 2025 12:08PM
BriaCell receives New Zealand patent for whole cell cancer technology Jul 30, 2025 07:31AM
BriaCell Therapeutics (BCTX) Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025 May 23, 2025 07:42AM


Apr 16, 2025 07:31AM BriaCell Therapeutics (BCTX) Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
Feb 3, 2025 04:45PM BriaCell Therapeutics (BCTX) Announces Proposed Public Offering of Common Shares
Feb 3, 2025 07:31AM BriaCell Therapeutics (BCTX) Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS
Dec 2, 2024 07:50AM BriaCell Therapeutics (BCTX) Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
Oct 15, 2024 07:51AM BriaCell Therapeutics (BCTX) Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Study
Oct 1, 2024 02:05PM BriaCell Therapeutics (BCTX) Announces $5 Million Offering
Sep 11, 2024 12:10PM BriaCell Therapeutics (BCTX) Announces $8.5 Million Offering of Common Shares, Warrants
Sep 10, 2024 07:51AM BriaCell Therapeutics (BCTX) Announces Positive Pre-IND Meeting with FDA for Bria-PROS+ for Prostate Cancer